Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.

Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R.

Int J Mol Sci. 2016 May 25;17(6). pii: E803. doi: 10.3390/ijms17060803. Review.

2.

Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study.

Pignatelli P, Pastori D, Perticone F, Corazza GR, Violi F; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) Study group.

Eur J Intern Med. 2015 Oct;26(8):e31-3. doi: 10.1016/j.ejim.2015.06.007. Epub 2015 Jun 27. No abstract available.

PMID:
26123820
3.

Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study.

Violi F, Pastori D, Perticone F, Hiatt WR, Sciacqua A, Basili S, Proietti M, Corazza GR, Lip GY, Pignatelli P; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY group.

BMJ Open. 2015 May 21;5(5):e008026. doi: 10.1136/bmjopen-2015-008026.

4.

Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A.

World J Gastroenterol. 2015 Feb 28;21(8):2269-80. doi: 10.3748/wjg.v21.i8.2269. Review.

5.

Erratum to: medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.

Raparelli V, Proietti M, Buttà C, Di Giosia P, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F, Corazza GR, Violi F, Basili S; ARAPACIS Study Investigators; GIS Group.

Intern Emerg Med. 2015 Mar;10(2):261-5. doi: 10.1007/s11739-014-1166-4. No abstract available.

PMID:
25519853
6.

Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression.

Zampino R, Coppola N, Cirillo G, Boemio A, Minichini C, Marrone A, Stanzione M, Starace M, Durante-Mangoni E, Sagnelli E, Restivo L, Salzillo G, Fascione MC, Nevola R, Del Giudice EM, Adinolfi LE.

World J Hepatol. 2014 Sep 27;6(9):677-84. doi: 10.4254/wjh.v6.i9.677.

7.

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P.

World J Gastroenterol. 2014 Jun 21;20(23):7089-103. doi: 10.3748/wjg.v20.i23.7089. Review.

8.

Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.

Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P.

World J Gastroenterol. 2014 Apr 7;20(13):3410-7. doi: 10.3748/wjg.v20.i13.3410. Review.

9.

Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE.

World J Hepatol. 2013 Oct 27;5(10):528-40. doi: 10.4254/wjh.v5.i10.528. Review.

10.

Chronic HCV infection is a risk factor of ischemic stroke.

Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A.

Atherosclerosis. 2013 Nov;231(1):22-6. doi: 10.1016/j.atherosclerosis.2013.08.003. Epub 2013 Aug 15.

PMID:
24125405
11.

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators.

J Am Coll Cardiol. 2013 Dec 10;62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035. Epub 2013 Aug 14. No abstract available.

12.

The predictive value of steatosis in hepatitis C virus infection.

Adinolfi LE, Restivo L, Marrone A.

Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):205-13. doi: 10.1586/egh.13.7. Review.

PMID:
23445230
13.

Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.

Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A.

Atherosclerosis. 2012 Apr;221(2):496-502. doi: 10.1016/j.atherosclerosis.2012.01.051. Epub 2012 Feb 8.

PMID:
22385985
14.

Metabolic alterations and chronic hepatitis C: treatment strategies.

Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P.

Expert Opin Pharmacother. 2011 Oct;12(14):2215-34. doi: 10.1517/14656566.2011.597742. Epub 2011 Sep 2. Review.

PMID:
21883025
15.

Does vitamin E cure nonalcoholic steatohepatitis?

Adinolfi LE, Restivo L.

Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):147-50. doi: 10.1586/egh.11.27. No abstract available.

PMID:
21476908
16.

Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.

Adinolfi LE, Durante-Mangoni E, Salzillo M, Marrone A, Tripodi MF, Restivo L, Merola A, Zampino R, Ruggiero G.

Intern Emerg Med. 2009 Dec;4(6):485-90. doi: 10.1007/s11739-009-0290-z.

PMID:
19649689
17.

Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C.

Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, Sutti S, Marrone A, Ruggiero G, Albano E, Adinolfi LE.

J Hepatol. 2008 Mar;48(3):399-406. doi: 10.1016/j.jhep.2007.10.011. Epub 2007 Dec 3.

PMID:
18164507

Supplemental Content

Loading ...
Support Center